Abbonarsi

IL-13–associated epithelial remodeling correlates with clinical severity in nasal polyposis - 04/05/23

Doi : 10.1016/j.jaci.2022.12.826 
Maya E. Kotas, MD, PhD a, Neil N. Patel, MD b, Emily K. Cope, PhD c, Jose G. Gurrola, MD b, Andrew N. Goldberg, MD b, Steven D. Pletcher, MD b, d, Max A. Seibold, PhD e, f, g, Camille M. Moore, PhD e, h, , , Erin D. Gordon, MD a,
a Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California, San Francisco, Calif 
b Department of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, Calif 
c Center for Applied Microbiome Sciences, the Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Ariz 
d Surgical Service, ENT Section, San Francisco VA Medical Center, San Francisco, Calif 
e Center for Genes, Environment, and Health, National Jewish Health, Denver, Colo 
f Department of Pediatrics, National Jewish Health, Denver, Colo 
g Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado, Aurora, Colo 
h Department of Biostatistics and Informatics, University of Colorado, Aurora, Colo 

Corresponding author: Erin D. Gordon, MD, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California, San Francisco, 513 Parnassus Ave, HSE 201, San Francisco, CA 94143.Division of PulmonaryCritical CareAllergy and Sleep MedicineDepartment of MedicineUniversity of CaliforniaSan Francisco513 Parnassus AveHSE 201San FranciscoCA94143∗∗Camille M. Moore, PhD, Center for Genes, Environment, and Health, National Jewish Health, 1400 Jackson St, Denver, CO 80206.Center for GenesEnvironmentand HealthNational Jewish Health1400 Jackson StDenverCO80206

Abstract

Background

Epithelial remodeling is a histopathologic feature of chronic inflammatory airway diseases including chronic rhinosinusitis (CRS). Cell-type shifts and their relationship to CRS endotypes and severity are incompletely described.

Objective

We sought to understand the relationship of epithelial cell remodeling to inflammatory endotypes and disease outcomes in CRS.

Methods

Using cell-type transcriptional signatures derived from epithelial single-cell sequencing, we analyzed bulk RNA-sequencing data from sinus epithelial brushings obtained from patients with CRS with and without nasal polyps in comparison to healthy controls.

Results

The airway epithelium in nasal polyposis displayed increased tuft cell transcripts and decreased ciliated cell transcripts along with an IL-13 activation signature. In contrast, CRS without polyps showed an IL-17 activation signature. IL-13 activation scores were associated with increased tuft cell, goblet cell, and mast cell scores and decreased ciliated cell scores. Furthermore, the IL-13 score was strongly associated with a previously reported activated (“polyp”) tuft cell score and a prostaglandin E2 activation signature. The Lund-Mackay score, a computed tomographic metric of sinus opacification, correlated positively with activated tuft cell, mast cell, prostaglandin E2, and IL-13 signatures and negatively with ciliated cell transcriptional signatures.

Conclusions

These results demonstrate that cell-type alterations and prostaglandin E2 stimulation are key components of IL-13–induced epithelial remodeling in nasal polyposis, whereas IL-17 signaling is more prominent in CRS without polyps, and that clinical severity correlates with the degree of IL-13–driven epithelial remodeling.

Il testo completo di questo articolo è disponibile in PDF.

Graphical abstract




Il testo completo di questo articolo è disponibile in PDF.

Key words : Chronic rhinosinusitis, nasal polyposis, type 2 inflammation, endotype, IL-13, prostaglandin E2, epithelial remodeling

Abbreviations used : CRS, CRSsNP, CRSwNP, LM, PGE2, scSeq, UCSF


Mappa


 This work was supported by the National Institutes of Health (grant no. 5R01AI136962 to E.D.G.; grant nos. R01HL128439, R01HL135156, and P01HL132821 to M.A.S.; grant nos. F32HL140868 and T32HL007185 to M.E.K.; and grant no. F32HL158174 to C.A.S.), the Department of Defense (M.A.S.), the A.P. Giannini Foundation (M.E.K.), the Webb-Waring Early Career Investigator Award from the Boettcher Foundation (C.M.M.), the Nina Ireland Program for Lung Health at UCSF (E.D.G. and M.E.K.), the UCSF John A. Watson Faculty Scholar Fund (J.G.G.), and the SABRE Center at UCSF (E.D.G.).
 Disclosure of potential conflict of interest: J. G. Gurrola II is a Genentech Advisory Board Consultant with agreement ending December 2021. A. N. Goldberg is a minor stock holder in Siesta Medical. S. D. Pletcher and A. N. Goldberg are coinventors of patent 14/394, 006 Sinus diagnostics and treatments. The rest of the authors declare that they have no relevant conflicts of interests.


© 2023  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 151 - N° 5

P. 1277-1285 - Maggio 2023 Ritorno al numero
Articolo precedente Articolo precedente
  • Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation
  • Ayobami T. Akenroye, Jodi B. Segal, Guohai Zhou, Dinah Foer, Lily Li, G. Caleb Alexander, Corinne A. Keet, John W. Jackson
| Articolo seguente Articolo seguente
  • Alterations of nasal microbiome in eosinophilic chronic rhinosinusitis
  • Yibo Liang, Runxiang Xie, Xin Xiong, Zhanjun Hu, Xiang Mao, Xiaoyu Wang, Jinmei Zhang, Peiyong Sun, Zhenzhong Yue, Wei Wang, Guimin Zhang

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.